Merus NV
NASDAQ:MRUS
Merus NV
Depreciation & Amortization
Merus NV
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Merus NV
NASDAQ:MRUS
|
Depreciation & Amortization
$2.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
||
Pharming Group NV
AEX:PHARM
|
Depreciation & Amortization
$15.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
||
ProQR Therapeutics NV
NASDAQ:PRQR
|
Depreciation & Amortization
€2.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
||
Uniqure NV
NASDAQ:QURE
|
Depreciation & Amortization
$12.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
24%
|
||
argenx SE
XBRU:ARGX
|
Depreciation & Amortization
$117.2m
|
CAGR 3-Years
183%
|
CAGR 5-Years
142%
|
CAGR 10-Years
N/A
|
||
LAVA Therapeutics NV
NASDAQ:LVTX
|
Depreciation & Amortization
$1.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Merus NV
Glance View
Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.
See Also
What is Merus NV's Depreciation & Amortization?
Depreciation & Amortization
2.5m
USD
Based on the financial report for Sep 30, 2024, Merus NV's Depreciation & Amortization amounts to 2.5m USD.
What is Merus NV's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
17%
Over the last year, the Depreciation & Amortization growth was 13%. The average annual Depreciation & Amortization growth rates for Merus NV have been 17% over the past three years , 17% over the past five years .